undamentalytics Newsletter
Sign in

Scilex Holding Co income statement

In fiscal 2025, Scilex Holding Co reported revenue of $30.3m, down 46.5% on the year before, operating income of −$346m (a -1143.7% margin) and net income of −$374m, or −$36.48 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue24313847573032
Cost of revenue241116171114
Gross profit2128273116712618
Research and development109913102119
Selling, general and administrative435165120119267278
Operating income−35−36−51−105−83−346−359
Interest expense131210121116
Income before tax−48−88−23−114−73−374−465
Income tax−0000−00—
Net income−48−88−23−114−73−374−465
Diluted EPS−$2.54−$338.34−$85.85−$646.38−$8.05−$36.48—
Diluted shares (average)19m——258m—11m—
EBITDA−31−32−47−101−79−341−354

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: SCLX vs VRCASBFM vs SCLXJAGX vs SCLX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Scilex Holding Co's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Scilex Holding Co.